Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,304.40
(
0.71%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.46
(
-0.19%
)
Bitcoin
74,229.01
(
0.39%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: DewDiligence post# 123969

Tuesday, 07/26/2011 10:41:36 PM

Tuesday, July 26, 2011 10:41:36 PM

Post# of 257253
Re: Edurant -
It's not very surprising since there were question marks about Edurant's efficacy in comparison to Sustiva. I don't think Btripla will cannibalize Atripla sales to a great extent - there might be some usage in patients who have neuropsychiatric side effects with Atripla, but I don't envision much first line usage at all.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now